Text size :

Pharmaceuticals, Uda (Egualia): “China and USA are big players but Italy has significant manufacturing”

ADNKRONOS

November 9, 2026

Rome, Nov 9. (Adnkronos Health) – “For over twenty years, our companies have brought an essential contribution to the Italian market linked to patent expiration. It is clear that we operate in an absolutely globalized world, where China and the United States are playing a very important game also on resilience and sustainability, both of pharmaceutical spending and investments in production, research and development. Europe finds itself somewhat squeezed between these two continents.” This was stated by Michele Uda, general director of Egualia, speaking at the event ‘The future of pharmaceutical legislation: a system vision’, organized by Nuove Reti in Rome.

“Italy, in particular, has a competitive advantage, which is that of having a very significant manufacturing structure also for our sector, that of off-patent drugs. The important thing – he explained – is that these medicines, in order to be fully part of the tools available to the National Health Service, are placed in the minimum conditions to be sustainable from an economic and industrial point of view, so as to continue to play that competitive role. I believe that the initiative to revise the consolidated text on pharmaceutical legislation and also the measures currently under discussion in the budget law are moving in that direction.”

Regarding the reform of the Consolidated Text, for Egualia “there are some very important corrective measures that should be introduced. One above all: a revision of the payback mechanism, which essentially finds a differentiated implementation method between medicines no longer covered by patent, purchased through tender procedures by the Regions, therefore already bought at the lowest possible price and which have already undergone negotiation at the AIFA (Italian Medicines Agency) level. When payback is applied to all drugs indiscriminately, it is clear that a significant problem is created in terms of competition,” he added. “Consider that about one in three lots already goes deserted in tenders because the products are no longer sustainable. We are talking about oncological products, antibiotics, essential public health products that we only somehow notice when they are missing, and we must absolutely prevent them from no longer being available on the market,” he concluded.

Jiji Press

Related

Page TOP